{"id":125811,"date":"2022-05-20T14:45:10","date_gmt":"2022-05-20T14:45:10","guid":{"rendered":"https:\/\/ccs.ca\/?page_id=125811"},"modified":"2024-05-14T11:48:20","modified_gmt":"2024-05-14T15:48:20","slug":"recipiendaires-atherosclerose-hls","status":"publish","type":"page","link":"https:\/\/ccs.ca\/fr\/recipiendaires-atherosclerose-hls\/","title":{"rendered":"R\u00e9cipiendaires de la Bourse de recherche sur l’ath\u00e9roscl\u00e9rose SCC-HLS"},"content":{"rendered":"\n
Chercheur principal<\/th> | Titre de la proposition<\/th> | Montant de la bourse<\/th><\/tr><\/thead> | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Mark Chandy<\/strong> <\/td> Investigating the Safety and Efficacy of the Novel Cannabinoid Receptor 1 (CB1) Antagonist, Genistein for Attenuating Adverse Cardiovascular Events<\/td> | 35 000 $<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n | 2021<\/mark><\/h3>\n\n\n\n
|